齐洛维特马布维多丁针对ROR1作为淋巴瘤癌治疗的治疗方法
Michael L Wang1, Jacqueline C Barrientos2, Richard R Furman3
1University of Texas MD Anderson Cancer Center, Houston.
NEJM evidence
|February 6, 2024
概括
齐洛韦他马布维多丁 (ZV) 通过向ROR1.1,在严重预处理的淋巴细胞癌中显示出抗瘤活性. 这种抗体-药物结合体表现出良好的安全性,支持ROR1作为治疗点.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 受体氨酸激酶类孤儿受体1 (ROR1) 是一种表达在各种癌症类型上的胎内抗原.
- 齐洛韦他马布维多丁 (ZV) 是一种抗体-药物联合体,旨在利用一种新型抗癌有效载荷准ROR1.
研究的目的:
- 评估先前接受过治疗的淋巴状癌症患者中齐洛维塔马布维多丁 (ZV) 的安全性,耐受性,药理动力学和初步疗效.
- 为了确定ZV的推第二阶段剂量 (RP2D).
主要方法:
- 一个第一阶段,首次在人身上,剂量升级研究.
- 患有复发/耐药淋巴细胞癌的患者每3周内静脉注射ZV.
- 剂量水平在0.5至2.5毫克/公斤之间,并对安全性和有效性进行了评估.
主要成果:
- 招募了32名患有地幔细胞淋巴瘤,慢性淋巴细胞白血病,扩散性大B细胞淋巴瘤和其他淋巴细胞恶性瘤的患者.
- 根据药理动力学和安全性数据,根据药理动力学和安全性数据,每3周确定推的ZV剂量为2.5mg/kg.
- 在47%的地幔细胞淋巴瘤患者和60%的扩散大B细胞淋巴瘤患者中观察到客观瘤反应.
结论:
- 齐洛韦他马布维多丁 (ZV) 在临床上证明了在淋巴细胞癌症中用于ROR1向治疗的概念.
- ZV显示可控毒性,没有与ROR1向相关的意外安全问题.
- 这项研究支持进一步调查ZV作为ROR1阳性血液恶性瘤患者的潜在新疗法选择.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526